FDA approves Winrevair (sotatercept-csrk), a first-in-class treatment for adults with pulmonary arterial hypertension (PAH, WHO Group 1).- Merck Inc.,
Merck Inc.,, known as MSD outside of the United States and Canada, announced that the FDA has approved sotatercept-csrk (U.S. Brand Name: Winrevair, for injection, 45mg, 60mg) for the treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events.